|
AIM: RENE |
|
2 August 2019 |
ReNeuron Group plc
("ReNeuron" or the "Company")
Posting of Annual Report and Accounts and Notice of AGM
ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2019 and the Notice of the 2019 Annual General Meeting ("AGM") have been sent to shareholders and are also available on the Company's website at www.reneuron.com.
ReNeuron's AGM will be held at 10.00am on Thursday 12 September 2019 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.
ENDS
Enquiries:
|
ReNeuron |
+44 (0) 20 3819 8400 |
|
Olav Hellebø, Chief Executive Officer |
|
|
Michael Hunt, Chief Financial Officer |
|
|
Buchanan |
+44 (0) 20 7466 5000 |
|
Mark Court, Sophie Wills, Tilly Abraham |
|
|
|
|
|
Stifel Nicolaus Europe Limited Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) |
+44 (0) 20 7710 7600 |
|
N+1 Singer Aubrey Powell, James Moat, Iqra Amin (Joint Broker) |
+44 (0) 20 7496 3000 |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
